Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS‐LED trial)

DiscussionAdministration of human choriogonadotropin alfa followed by erythropoietin is safe after a new ischemic stroke. At the doses studied, placebo and active groups did not differ significantly in neurological recovery. Study limitations, such as the use of multiple assessors, differences in rehabilitation care, and being underpowered to show efficacy, are discussed.

Source: International Journal of Stroke - February 1, 2014 Category: Neurology Authors: Steven C. Cramer, Michael D. Hill, Tags: Research Source Type: research